Company news
Zentalis Pharmaceuticals, Inc. news in 2024
Zentalis Pharmaceuticals, Inc.'s news releases, calls and decks from 2024, newest first.
Zentalis Pharmaceuticals Announces Key Management Appointments
December 11, 2024
Zentalis Pharmaceuticals Announces Executive Leadership Changes Supporting Planned Registrational Clinical Studies of Azenosertib
November 12, 2024
Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies
September 15, 2024
Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024
September 8, 2024
Zentalis Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Progress
August 8, 2024
Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program
June 17, 2024
Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of Directors
May 28, 2024
Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress
May 6, 2024
Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates
February 26, 2024
Zentalis Pharmaceuticals Strengthens Management Team with Key Appointments
January 24, 2024
Decks in 2024
- Investor Presentation (June 2024)
Investor deck · 61 slides · Jun 3, 2024
- Investor Presentation (April 2024)
Investor deck · 55 slides · Apr 9, 2024